### ü´† Cardiology: Peripheral Artery Disease and Statin Therapy

#### ‚úÖ True Statements
1. **Peripheral artery disease (PAD)** is considered a form of **clinical atherosclerotic cardiovascular disease (ASCVD)**.
2. Patients aged 75 years or younger with **ASCVD** should begin **high-intensity statin therapy** unless a contraindication exists.
3. **High-intensity statin therapy** includes **atorvastatin** (40 mg/d or 80 mg/d) and **rosuvastatin** (20 mg/d or 40 mg/d).
4. **Ezetimibe** impairs **intestinal cholesterol absorption** and significantly reduces **low-density lipoprotein (LDL) cholesterol** levels when added to statin therapy.
5. **Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors**, such as **evolocumab**, significantly reduce **LDL cholesterol** and are approved as adjunctive therapy in patients with **familial hypercholesterolemia** or **very high-risk ASCVD** who have not reached LDL goals on maximally tolerated lipid-lowering therapy.
6. **Treatment with evolocumab** has been associated with reduced risk of **myocardial infarction**, **stroke**, **hospitalization for unstable angina**, and **coronary revascularization**, but not with reduced **cardiovascular or all-cause mortality**.
7. **Moderate-intensity statin therapy** is not the first-line treatment in patients aged 75 years or younger with **clinical ASCVD**; it is an option in patients older than 75 years or those with contraindications to high-intensity statins.

#### üí¨ Extra
1. An ankle‚Äìbrachial index (ABI) less than 0.90 is diagnostic for PAD and confirms the presence of ASCVD.
2. Ezetimibe is not appropriate as monotherapy in patients not already taking a statin.
5. Very high-risk ASCVD is defined as multiple ASCVD events or one event with multiple risk factors, and an LDL cholesterol level ‚â•70 mg/dL or non‚ÄìHDL cholesterol ‚â•100 mg/dL despite maximal therapy.
6. Despite improvements in nonfatal cardiovascular outcomes, PCSK9 inhibitors like evolocumab have not demonstrated a mortality benefit in clinical trials.
7. The benefit of high-intensity statins outweighs moderate-intensity options in patients ‚â§75 years with ASCVD due to superior LDL lowering and cardiovascular risk reduction.

#### üî∑ Tags
#Cardiology #AmbulatoryCare #PeripheralArteryDisease #StatinTherapy #ASCVD #LDLCholesterol #HighIntensityStatin #PCSK9Inhibitor #Ezetimibe

#### üìô Reference
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2019;139:e1082-1143. PMID: 30586774 doi:10.1161/CIR.0000000000000625

#### üÜî Question ID
CVQQQ24022

#### üïí Last Updated
January 2025

---

#### üìñ Related Text
MKSAP 19: Cardiovascular Medicine ‚Äî Management of Dyslipidemias

---

### üìò Related Text Derivations

#### ‚úÖ True Statements
1. **Peripheral artery disease (PAD)** is a qualifying condition for **secondary prevention** of **atherosclerotic cardiovascular disease (ASCVD)**.
2. **High-intensity statin therapy** should be initiated in patients aged 75 years or younger with **ASCVD** to achieve ‚â•50% reduction in **LDL cholesterol**.
3. If **high-intensity statin therapy** is contraindicated or not tolerated, **moderate-intensity statin therapy** should be used to achieve a 30%‚Äì49% reduction in **LDL cholesterol**.
4. If LDL cholesterol remains ‚â•70 mg/dL on statin therapy alone, **ezetimibe** should be added.
5. If LDL goals remain unmet after adding **ezetimibe**, a **PCSK9 monoclonal antibody** may be considered.
6. **Patients with very high risk ASCVD** (multiple ASCVD events or one ASCVD event plus multiple high-risk conditions) may benefit from **nonstatin therapy** in addition to **maximally tolerated statin therapy**.
7. **Bempedoic acid** or **inclisiran** may be considered if LDL cholesterol remains elevated after ezetimibe and PCSK9 inhibitor use.
8. The **American Diabetes Association (ADA)** recommends **high-intensity statin therapy** for all patients with **diabetes** and **ASCVD**.
9. The **U.S. Department of Veterans Affairs** and **Department of Defense cholesterol guideline** recommends **moderate- to high-intensity statin therapy** in ASCVD patients and considers **nonstatin therapies** in high-risk individuals.

#### üí¨ Extra
1. Secondary prevention includes patients with ACS, prior MI, stable/unstable angina, stroke, TIA, PAD, and aortic aneurysm.
5. PCSK9 monoclonal antibody cost has decreased, improving its cost-effectiveness.
7. These newer agents are options for patients with statin intolerance or extremely high baseline LDL levels.
8. This is consistent with AHA/ACC guidelines and emphasizes diabetes as a major ASCVD risk enhancer.
9. High-risk criteria include recent MI, recurrent vascular events, or additional risk factors like diabetes or CKD.

#### üî∑ Tags
#Cardiology #Dyslipidemia #SecondaryPrevention #LDLCholesterol #HighIntensityStatin #Ezetimibe #PCSK9Inhibitor #BempedoicAcid #Inclisiran #Diabetes #VeteransGuidelines

---

### üñºÔ∏è Supplemental Figures

<!-- VA/DoD Dyslipidemia Recommendations Table -->
<table>
  <caption><strong>Summary of the U.S. Department of Veterans Affairs/U.S. Department of Defense Dyslipidemia Pharmacotherapy Recommendations</strong></caption>
  <thead>
    <tr>
      <th>Recommendation Topic</th>
      <th>Conclusion</th>
    </tr>
  </thead>
  <tbody>
    <tr><td colspan="2"><strong>Primary Prevention</strong></td></tr>
    <tr>
      <td>Moderate-intensity statin therapy for patients with a 10-year CVD risk ‚â•12%, an LDL cholesterol level ‚â•190 mg/dL (4.92 mmol/L), or diabetes mellitus</td>
      <td>Recommended</td>
    </tr>
    <tr>
      <td>Moderate-intensity statin therapy for patients with a 10-year CVD risk between 6% and 12%</td>
      <td>Suggested if patient prefers treatment</td>
    </tr>
    <tr>
      <td>PCSK9 inhibitors</td>
      <td>Recommended against</td>
    </tr>
    <tr>
      <td>Ezetimibe</td>
      <td>No recommendation</td>
    </tr>
    <tr><td colspan="2"><strong>Secondary Prevention</strong></td></tr>
    <tr>
      <td>At least moderate-intensity statin therapy</td>
      <td>Recommended</td>
    </tr>
    <tr>
      <td>High-intensity statin therapy for higher-risk patients<sup>a,b</sup></td>
      <td>Suggested</td>
    </tr>
    <tr>
      <td>Adding ezetimibe to statin therapy for higher-risk patients<sup>a,b</sup></td>
      <td>Suggested</td>
    </tr>
    <tr>
      <td>PCSK9 inhibitor for higher-risk patients<sup>b,c</sup></td>
      <td>Suggested</td>
    </tr>
    <tr><td colspan="2"><strong>Other Medications, Supplements, and Nutraceuticals</strong></td></tr>
    <tr>
      <td>Adding icosapent ethyl to statin therapy for secondary prevention in patients with persistently elevated fasting triglyceride levels &gt;150 mg/dL (1.69 mmol/L)</td>
      <td>Suggested</td>
    </tr>
    <tr>
      <td>Niacin for primary or secondary prevention</td>
      <td>Recommended against</td>
    </tr>
    <tr>
      <td>Adding fibrates to statin therapy for primary or secondary prevention</td>
      <td>Suggested against</td>
    </tr>
    <tr>
      <td>Omega-3 fatty acids as dietary supplements for primary or secondary prevention</td>
      <td>Suggested against</td>
    </tr>
    <tr>
      <td>Adding icosapent ethyl to statin therapy for primary prevention in patients with persistently elevated fasting triglyceride levels &gt;150 mg/dL (1.69 mmol/L)</td>
      <td>No recommendation</td>
    </tr>
    <tr><td colspan="2"><strong>Monitoring</strong></td></tr>
    <tr>
      <td>Routine monitoring of lipid levels in patients receiving statin therapy</td>
      <td>Suggested against</td>
    </tr>
  </tbody>
</table>

<p><em>
CVD = cardiovascular disease; PCSK9 = proprotein convertase subtilisin/kexin type 9.<br>
<sup>a</sup> In patients who are willing to intensify treatment after discussing the risk of high-intensity statin therapy.<br>
<sup>b</sup> Higher-risk patients include those with a myocardial infarction or acute coronary syndrome in the past 12 months; recurrent acute coronary syndrome, myocardial infarction, or stroke; or established CVD with additional risk factors (e.g., currently smoking, diabetes, peripheral artery disease, or coronary revascularization).<br>
<sup>c</sup> In patients who are willing to intensify treatment after discussing the uncertain long-term safety and benefits.
</em></p>

<p>
Information from O'Malley PG, Arnold MJ, Kelley C, et al. Management of Dyslipidemia for Cardiovascular Disease Risk Reduction: Synopsis of the 2020 Updated U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline. <em>Ann Intern Med</em>. 2020;173:822‚Äì829. <a href="https://doi.org/10.7326/M20-0580">PMID: 32956597</a>
</p>
